ROBERTO MIRANDA to Protein Kinase Inhibitors
This is a "connection" page, showing publications ROBERTO MIRANDA has written about Protein Kinase Inhibitors.
Connection Strength
0.239
-
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6.
Score: 0.126
-
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer J. 2016 05 06; 6:e418.
Score: 0.045
-
Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500.
Score: 0.035
-
Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis. Hum Pathol. 2012 Dec; 43(12):2223-8.
Score: 0.034